Does a daily low-dose aspirin help healthy older adults live longer?
Claim attributed to Longevity-minded older adults who self-prescribe daily aspirin for primary prevention , A lay belief carried over from 1980s-90s trial-era enthusiasm and decades of "an aspirin a day" messaging. No major guideline body now recommends it for healthy people.
This was tested directly and it failed: in healthy older adults, daily aspirin produced no longer disability-free life, more major bleeding, and slightly more deaths. It is disproven for primary prevention, not merely untested.
It nudges a clotting pathway, not the aging clock; the one trial built to measure longer healthy life found none, plus more bleeding and deaths.
What it’s supposed to target
- Platelet COX-1 / thromboxane
- Antiplatelet (anti-clotting) effect
- Vascular inflammation
- Colorectal cancer pathways
Aspirin irreversibly blocks COX-1 in platelets, cutting thromboxane A2 and making platelets less sticky. The longevity rationale: fewer clots means fewer heart attacks and strokes, and aspirin's anti-inflammatory and possible anti-cancer effects (notably colorectal) might add years. For people who have ALREADY had a cardiovascular event (secondary prevention), this antiplatelet effect genuinely lowers repeat events, which is where the 'an aspirin a day' idea came from.
The mechanism is real but double-edged, and that is the whole problem for healthy people. The same antiplatelet action that prevents clots also causes bleeding, including gastrointestinal and brain hemorrhage. In low-risk older adults there are few clots to prevent, so the bleeding harm outweighs any benefit, which is exactly what the ASPREE trial found. A plausible pathway does not survive contact with the trial in this population.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
Aspirin's antiplatelet effect would have to prevent more events than the bleeding it causes in healthy, low-risk elders: ASPREE shows it does not.
The prevented-events benefit would have to translate into longer disability-free life: it did not (HR 1.01).
Overall mortality would at least not rise: instead it rose slightly (HR 1.14), driven by cancer deaths, the opposite of a longevity effect.
What the evidence actually shows
The trial built to test this question found nothing
ASPREE randomized 19,114 community-dwelling adults aged 70+ to 100 mg enteric-coated aspirin or placebo for a median 4.7 years. The primary endpoint, disability-free survival (free of death, dementia, or persistent physical disability), was identical: 21.5 vs 21.2 events per 1000 person-years (HR 1.01, 95% CI 0.92-1.11, P=0.79). Cardiovascular events showed no significant net benefit (HR 0.95, CI 0.83-1.08). The trial was government-funded by the US National Institute on Aging and Australia's NHMRC, with no commercial stake in the result.
Real harm, and a mortality signal pointing the wrong way
Aspirin significantly increased major hemorrhage: 8.6 vs 6.2 events per 1000 person-years (HR 1.38, 95% CI 1.18-1.62, P<0.001). All-cause mortality was also higher on aspirin, 12.7 vs 11.1 deaths per 1000 person-years (HR 1.14, 95% CI 1.01-1.29), driven largely by cancer death (3.1% vs 2.3%). On this evidence the 2022 USPSTF issued a Grade D recommendation against starting aspirin for primary prevention in adults 60+.
Studies, graded, and who paid
ASPREE found no difference (HR 1.01, 95% CI 0.92-1.11, P=0.79).
No significant net benefit; the CI crossed 1 (HR 0.95, 0.83-1.08).
Major hemorrhage rose significantly (HR 1.38, 1.18-1.62).
Still guideline-recommended, but a different population and question.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 1 | ASPREE, disability-free survival | Randomized controlled trial (primary prevention) | 19,114 adults 70+ | Independent US NIA and Australian NHMRC; government-funded. | Median 4.7 yr; applies to healthy elders, not secondary prevention. |
| 2 | ASPREE, CVD and bleeding | Randomized controlled trial (primary prevention) | 19,114 randomized | Independent US NIA and NHMRC; no industry funding. | No net CVD benefit; bleeding increase is the firm finding. |
| 3 | ASPREE, all-cause mortality | Randomized controlled trial (primary prevention) | 19,114 randomized | Independent US NIA and others; government-funded. | Cancer-mortality signal was not pre-specified; interpret cautiously. |
| 4 | USPSTF 2022 recommendation | Evidence-based clinical guideline | Systematic evidence review | Independent AHRQ-supported government panel; non-industry. | Adults 40-59 are a separate individualized Grade C decision. |
The claim conflates two questions: aspirin still helps people with established cardiovascular disease (secondary prevention), but fails for healthy people taking it preventively.
Unproven ≠ disproven
This is not a gap in the evidence: a large RCT was funded specifically to answer it and returned a clear null-to-harmful result.
Where claim and evidence diverge
Believers cite a heart-attack-prevention rationale that simply does not hold in low-risk elders, where bleeding harm overtakes any cardiovascular gain.
The money trail
The decisive evidence is independent: ASPREE and the USPSTF panel were government-funded with no aspirin sales at stake, so null and harm findings cannot be dismissed as suppression. Aspirin is a cheap generic; the belief survives on culture, not sponsored studies.
The honest read
For a healthy older adult, daily aspirin does not extend life or prevent age-related decline, and it raises bleeding risk. If you have established heart disease, that is a different conversation with your doctor.
What would change this verdict
A large independent RCT in healthy older adults showing aspirin improves disability-free survival or lowers all-cause mortality.
A guideline body reversing the Grade D and re-recommending aspirin for primary prevention on new evidence.
Sources
- McNeil JJ, Woods RL, Nelson MR, et al. Effect of Aspirin on Disability-free Survival in the Healthy Elderly. N Engl J Med. 2018;379(16):1499-1508.
- McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018;379(16):1509-1518.
- McNeil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018;379(16):1519-1528.
- US Preventive Services Task Force. Aspirin Use to Prevent Cardiovascular Disease: Recommendation Statement. JAMA. 2022;327(16):1577-1584.
- American College of Cardiology. New USPSTF Recommendation on Aspirin in CVD: No For Primary Prevention, Yes For Secondary Prevention. ACC.org, 2022.
- ASPREE Trial Summary. American College of Cardiology, Latest in Cardiology, 2018.
People also ask
- Does a daily aspirin help healthy older adults live longer?
- No. The ASPREE trial in adults 70 and older found daily 100 mg aspirin produced no longer disability-free life (HR 1.01) and no all-cause mortality benefit. All-cause death was actually slightly higher on aspirin (HR 1.14), driven largely by cancer deaths.
- What are the risks of taking low-dose aspirin every day?
- Daily aspirin significantly raises major bleeding risk. In ASPREE, major hemorrhage rose to 8.6 versus 6.2 events per 1000 person-years (HR 1.38). For this reason the 2022 USPSTF issued a Grade D recommendation against starting aspirin for primary prevention in adults 60 and older.
- Should I take aspirin if I already had a heart attack or stroke?
- That is a separate question. Aspirin remains guideline-recommended for secondary prevention in people with established cardiovascular disease. The evidence against daily aspirin applies to healthy, low-risk people taking it preventively, not to those with a prior cardiovascular event. Discuss your case with your doctor.
- Why do people still believe in an aspirin a day?
- The belief survives on culture, not current evidence. It carried over from 1980s and 1990s trial-era enthusiasm and decades of marketing. The decisive ASPREE trial and USPSTF panel were government-funded with no aspirin sales at stake, so the null and harm findings cannot be dismissed as suppression.
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.